, Tracking Stock Market Picks
Enter Symbol:
Rating: MED
In-line $32
up 17.00 %

Medifast Inc (NYSE: MED) reiterated to In-line with price target $32 by Imperial Capital

Friday,  Nov 7, 2014  8:25 AM ET by Lynn Gilbert

Imperial Capital reiterated Medifast Inc (NYSE: MED) to In-line with price target $32. Previously, Imperial Capital rated Medifast Inc (NYSE: MED) to Outperform with price
target $34 on 08/08/2014, when the stock price was valued at $26.15. Since then, Medifast Inc's stock price has gained 17% as of 11/07/2014's recent price of $30.56.
If you had followed Imperial Capital's previous recommendation on MED, you would have gained 17% of your investment in 91 days.

Medifast, Inc. (Medifast) is engaged in the production, distribution, and sale of weight management and disease management products and other consumable health and diet products. The Company?s product lines include weight and disease management, meal replacement, and vitamins primarily manufactured in its modern, the United States Food and Drug Administration (FDA) approved facility in Owings Mills, Maryland. The Company?s operations are primarily conducted through five of its wholly owned subsidiaries, Jason Pharmaceuticals, Inc. (Jason), Take Shape for Life, Inc. (TSF), Jason Enterprises, Inc., Jason Properties, LLC and Seven Crondall, LLC. The Company offers a variety of weight and disease management products under the Medifast brand and for select private label customers. It's distribution channels include Medifast Direct, Take Shape for Life, Medifast Weight Control Centers and Medifast Physicians.

Imperial Capital

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy